Abstract

Bumetanide 0.5-mg, 1-mg, or 2-mg Capsules

Author(s): Allen Loyd V Jr

Issue: May/Jun 2014 - Volume 18, Number 3

Page(s): 233

Download in electronic PDF format for $75

Abstract

A formulation for preparing Bumetanide 0.5-mg, 1-mg, or 2-mg Capsules. Includes ingredients, method of preparation, discussion, and references for the compounding pharmacist.

Related Keywords

Related Categories

Printer-Friendly Version

Related Articles from IJPC

Issue/Page View/Buy	Title/Author (Click for Abstract / Details / Purchase)
May/Jun 2004 Pg. 181-185	Compounding in the Pharmacy Curriculum: Beyond the Basics Author(s): Hinkle Amanda R, Newton Gail D
May/Jun 2014 Pg. 233	Bumetanide 0.5-mg, 1-mg, or 2-mg Capsules Author(s): Allen Loyd V Jr
Nov/Dec 2004 Pg. 462-465	Basics of Compounding for Cough Author(s): Allen Loyd V Jr
Jan/Feb 2014 Pg. 61	Bumetanide 0.25-mg/mL Injection Author(s): Allen Loyd V Jr
Jul/Aug 2003 Pg. 288-291	Basics of Compounding for Raynaud's Disease Author(s): Glasnapp Andrew
May/Jun 2003 Pg. 188-191	Treating Canine Hepatic Disease Author(s): Davidson Gigi S
Sep/Oct 2009 Pg. 367-371	Congestive Heart Failure and Other Medical Facts About Ferrets; Scout's Story: A Case Report on Treating Congestive Heart Failure in a Ferret Author(s): Williams LaVonn A, Riley Kari
Mar/Apr 2010 Pg. 108-111	Coenzyme Q10 Supplementation in the Treatment of Heart Disease Author(s): Bramwell Bethany L
May/Jun 2013 Pg. 230	Estradiol 0.5-mg, 1-mg, or 2-mg Capsules Author(s): Allen Loyd V Jr
Nov/Dec 2017 Pg. 496	Spironolactone 5 mg/mL in SuspendIt Oral Suspension Author(s): Allen Loyd V Jr
May/Jun 2022 Pg. 248-254	Physical and Chemical Stability of Pharmaceutical Preparation of Bumetanide and Scopolamine Author(s): Catry Emilie, Colsoul Marie-Louise, Closset Melanie, Hubert Justine, Soumoy Laura, Bihin Benoit, Thiry Emmanuell, Jamart Jacques, Hecq Jean-Daniel, Galanti Laurence
Sep/Oct 2010 Pg. 382-394	Conservative Management of Chronic Kidney Disease in Cats: Recommendations for Veterinarians and Compounding Pharmacists Author(s): Meadows Richard L, Muller George
Mar/Apr 2014 Pg. 142	Doxazosin 1-mg, 2-mg, 4-mg, or 8-mg Capsules Author(s): Allen Loyd V Jr
May/Jun 2014 Pg. 241	Thiothixene 1-mg, 2-mg, 5-mg, or 10-mg Capsules Author(s): Allen Loyd V Jr
Sep/Oct 2019 Pg. 414-417	Stability of Furosemide 5 mg/mL in Polypropylene Syringes Author(s): van der Schaar JAJ, Grouls R, Franssen EJF, Crul M
Mar/Apr 2016 Pg. 145	Carvedilol 3.125-mg, 6.25-mg, 12.5 mg, or 25-mg capsules Author(s): Allen Loyd V Jr
Jan/Feb 2002 Pg. 16-18	Compounding for Diseases of the Oral Cavity: A discussion with Stu Sommerville, RPh Author(s): Vail Jane
May/Jun 2006 Pg. 227	Quinapril 1-mg/mL Oral Liquid Author(s): Allen Loyd V Jr
Jul/Aug 2015 Pg. 333	Tacrolimus Capsules, 0.5 mg, 1 mg, or 5 mg Author(s): Allen Loyd V
Sep/Oct 2022 Pg. 436-439	Effects of Calcium Polystyrene Sulfonate Formulation Change from Dry Syrup to Oral Solution in Patients with Chronic Kidney Disease Author(s): Kobayashi Shunsuke, Ogawara Yuka, Imamura Yoshihiko, Kitaoka Akira, Yasu Takeo